Clinical Trial Update: STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for STA-9090 in patients with advanced esophagogastric cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Cancer

Drugs mentioned

• STA-9090 (ganetespib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Esophagogastric Cancer | Phase 2 | Status: COMPLETED